TBPH Annual CFI
-$32.70 M
-$1.19 B-102.83%
31 December 2023
Summary:
As of January 23, 2025, TBPH annual cash flow from investing activities is -$32.70 million, with the most recent change of -$1.19 billion (-102.83%) on December 31, 2023. During the last 3 years, it has fallen by -$43.42 million (-404.98%). TBPH annual CFI is now -102.83% below its all-time high of $1.15 billion, reached on December 31, 2022.TBPH Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TBPH Quarterly CFI
-$17.40 M
-$14.37 M-474.03%
30 September 2024
Summary:
As of January 23, 2025, TBPH quarterly cash flow from investing activities is -$17.40 million, with the most recent change of -$14.37 million (-474.03%) on September 30, 2024. Over the past year, it has dropped by -$17.38 million (-82752.38%). TBPH quarterly CFI is now -101.62% below its all-time high of $1.08 billion, reached on September 30, 2022.TBPH Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TBPH TTM CFI
-$4.08 M
-$17.38 M-130.67%
30 September 2024
Summary:
As of January 23, 2025, TBPH TTM cash flow from investing activities is -$4.08 million, with the most recent change of -$17.38 million (-130.67%) on September 30, 2024. Over the past year, it has dropped by -$11.22 million (-157.12%). TBPH TTM CFI is now -100.35% below its all-time high of $1.15 billion, reached on December 31, 2022.TBPH TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TBPH Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -102.8% | -10000.0% | -157.1% |
| 3 y3 years | -405.0% | +51.4% | -102.5% |
| 5 y5 years | -118.5% | -133.2% | -138.1% |
TBPH Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -102.8% | at low | -101.6% | +59.6% | -100.3% | +87.5% |
| 5 y | 5-year | -102.8% | +60.6% | -101.6% | +90.2% | -100.3% | +96.5% |
| alltime | all time | -102.8% | +77.9% | -101.6% | +90.2% | -100.3% | +98.6% |
Theravance Biopharma Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$17.40 M(+474.0%) | -$4.08 M(-130.7%) |
| June 2024 | - | -$3.03 M(-117.8%) | $13.30 M(-51.4%) |
| Mar 2024 | - | $17.03 M(-2615.2%) | $27.38 M(-183.7%) |
| Dec 2023 | -$32.70 M(-102.8%) | -$677.00 K(+3123.8%) | -$32.70 M(-557.9%) |
| Sept 2023 | - | -$21.00 K(-100.2%) | $7.14 M(-99.3%) |
| June 2023 | - | $11.05 M(-125.7%) | $1.08 B(+0.3%) |
| Mar 2023 | - | -$43.05 M(-209.9%) | $1.08 B(-6.5%) |
| Dec 2022 | $1.15 B(+827.0%) | $39.16 M(-96.4%) | $1.15 B(+2.5%) |
| Sept 2022 | - | $1.08 B(>+9900.0%) | $1.13 B(+7679.4%) |
| June 2022 | - | $7.51 M(-76.5%) | $14.47 M(-66.1%) |
| Mar 2022 | - | $31.92 M(+194.9%) | $42.72 M(-65.7%) |
| Dec 2021 | $124.49 M(+1061.2%) | $10.82 M(-130.2%) | $124.49 M(-25.0%) |
| Sept 2021 | - | -$35.79 M(-200.1%) | $166.04 M(-38.1%) |
| June 2021 | - | $35.77 M(-68.5%) | $268.37 M(+379.1%) |
| Mar 2021 | - | $113.70 M(+117.1%) | $56.02 M(+422.5%) |
| Dec 2020 | $10.72 M(-112.9%) | $52.37 M(-21.3%) | $10.72 M(-138.9%) |
| Sept 2020 | - | $66.54 M(-137.7%) | -$27.59 M(-76.6%) |
| June 2020 | - | -$176.59 M(-358.2%) | -$117.78 M(-304.8%) |
| Mar 2020 | - | $68.40 M(+386.5%) | $57.51 M(-169.2%) |
| Dec 2019 | -$83.05 M(-147.0%) | $14.06 M(-159.4%) | -$83.05 M(-3741.0%) |
| Sept 2019 | - | -$23.66 M(+1725.3%) | $2.28 M(-96.9%) |
| June 2019 | - | -$1.30 M(-98.2%) | $72.58 M(-37.3%) |
| Mar 2019 | - | -$72.16 M(-172.6%) | $115.84 M(-34.4%) |
| Dec 2018 | $176.71 M | $99.39 M(+113.1%) | $176.71 M(+49.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | $46.65 M(+11.2%) | $118.56 M(+36.8%) |
| June 2018 | - | $41.96 M(-471.5%) | $86.68 M(+55.1%) |
| Mar 2018 | - | -$11.29 M(-127.4%) | $55.90 M(-199.2%) |
| Dec 2017 | -$56.33 M(-62.0%) | $41.25 M(+179.4%) | -$56.33 M(-60.8%) |
| Sept 2017 | - | $14.76 M(+32.1%) | -$143.79 M(-31.0%) |
| June 2017 | - | $11.18 M(-109.0%) | -$208.39 M(-27.7%) |
| Mar 2017 | - | -$123.52 M(+167.3%) | -$288.14 M(+94.4%) |
| Dec 2016 | -$148.24 M(-233.5%) | -$46.20 M(-7.3%) | -$148.24 M(+8.6%) |
| Sept 2016 | - | -$49.84 M(-27.3%) | -$136.53 M(+454.9%) |
| June 2016 | - | -$68.58 M(-518.5%) | -$24.60 M(-128.9%) |
| Mar 2016 | - | $16.39 M(-147.5%) | $85.27 M(-23.2%) |
| Dec 2015 | $111.04 M(-204.5%) | -$34.50 M(-155.6%) | $111.04 M(-28.5%) |
| Sept 2015 | - | $62.09 M(+50.3%) | $155.23 M(-1028.4%) |
| June 2015 | - | $41.30 M(-2.0%) | -$16.72 M(-73.2%) |
| Mar 2015 | - | $42.15 M(+335.3%) | -$62.48 M(-41.2%) |
| Dec 2014 | -$106.25 M(+3933.8%) | $9.68 M(-108.8%) | -$106.25 M(-9.2%) |
| Sept 2014 | - | -$109.86 M(+2363.7%) | -$117.00 M(+1484.9%) |
| June 2014 | - | -$4.46 M(+175.2%) | -$7.38 M(+104.3%) |
| Mar 2014 | - | -$1.62 M(+52.0%) | -$3.61 M(+37.2%) |
| Dec 2013 | -$2.63 M(+8.4%) | -$1.07 M(+349.8%) | -$2.63 M(+68.0%) |
| Sept 2013 | - | -$237.00 K(-65.7%) | -$1.57 M(+17.8%) |
| June 2013 | - | -$691.00 K(+8.0%) | -$1.33 M(+108.0%) |
| Mar 2013 | - | -$640.00 K | -$640.00 K |
| Dec 2012 | -$2.43 M | - | - |
FAQ
- What is Theravance Biopharma annual cash flow from investing activities?
- What is the all time high annual CFI for Theravance Biopharma?
- What is Theravance Biopharma annual CFI year-on-year change?
- What is Theravance Biopharma quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Theravance Biopharma?
- What is Theravance Biopharma quarterly CFI year-on-year change?
- What is Theravance Biopharma TTM cash flow from investing activities?
- What is the all time high TTM CFI for Theravance Biopharma?
- What is Theravance Biopharma TTM CFI year-on-year change?
What is Theravance Biopharma annual cash flow from investing activities?
The current annual CFI of TBPH is -$32.70 M
What is the all time high annual CFI for Theravance Biopharma?
Theravance Biopharma all-time high annual cash flow from investing activities is $1.15 B
What is Theravance Biopharma annual CFI year-on-year change?
Over the past year, TBPH annual cash flow from investing activities has changed by -$1.19 B (-102.83%)
What is Theravance Biopharma quarterly cash flow from investing activities?
The current quarterly CFI of TBPH is -$17.40 M
What is the all time high quarterly CFI for Theravance Biopharma?
Theravance Biopharma all-time high quarterly cash flow from investing activities is $1.08 B
What is Theravance Biopharma quarterly CFI year-on-year change?
Over the past year, TBPH quarterly cash flow from investing activities has changed by -$17.38 M (-82752.38%)
What is Theravance Biopharma TTM cash flow from investing activities?
The current TTM CFI of TBPH is -$4.08 M
What is the all time high TTM CFI for Theravance Biopharma?
Theravance Biopharma all-time high TTM cash flow from investing activities is $1.15 B
What is Theravance Biopharma TTM CFI year-on-year change?
Over the past year, TBPH TTM cash flow from investing activities has changed by -$11.22 M (-157.12%)